Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents
Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents
In about 10% of preoperative anaphylactic reactions to Neuro-Muscular Blocking Agents (NMBA)
 (114 patients analyzed at the BICHAT Hospital), a classical mechanism (mast cell- and
 IgE-dependent) is not identified. The mechanisms underlying these atypical anaphylactic
 reactions are unknown. The investigators have developed at the Pasteur Institute a murine
 model of anaphylaxis in which neutrophils, IgG and Platelet Activating Factor (PAF) play
 predominant roles. In addition, preliminary results obtained at the BICHAT Hospital suggest
 the presence of specific IgG anti-quaternary ammonium in the sera of patients that had
 developed a shock to NMBA anesthesia, but not in controls exposed to NMBA anesthesia or in
 normal blood donors. Finally, the release of neutrophil extracellular traps (NETs),
 extracellular filaments made of DNA and histones, may contribute to respiratory symptoms
 HYPOTHESIS: Neutrophils are implicated in NMBA -induced anaphylactic reactions in humans.
 Activated by IgG-NMBA complexes, which aggregate IgG receptors, neutrophils release PAF and
 NETs that are implicated in the cardiac and respiratory distress during anaphylaxis. It is
 possible that the activation of neutrophils: 1) explains the clinical features of atypical
 anaphylactic reactions (non-IgE mediated), 2) participates also in part to classical
 anaphylactic reactions GENERAL OBJECTIVE: Compare the percentage of circulating activated
 neutrophils in a group of patients immediately following a NMBA -induced shock (case) to that
 of a group of patients exposed to NMBA during anesthesia without developing a shock
 (control).

 SECONDARY OBJECTIVES:

 A) the day of the shock, quantify and compare between case and controls, 1) the level of
 circulating anti-quaternary ammonium IgG by immuno fluorometry, 2) the expression of IgG
 receptors (FcR) on the surface of neutrophils by cytometry, 3) the levels of circulating PAF
 by mass spectrometry, 4) the amount of NETs by immunofluorescence.

 B) 6 to 10 weeks after the shock perform, 1) cutaneous tests to NMBA, 2) a study of the
 capacity of stimulation of ex vivo neutrophils by IgG- NMBA complexes
Case control study, with a 6,10 week follow-up on cases

 Selection of cases :

 Inclusion criteria: Any patient of age 18 and over:

 Presenting with clinical signs compatible with a perioperative anaphylactic reaction to
 neuromuscular blocking drugs, whatever the grade of the anaphylactic reaction That was
 treated following the French Patient Management 2011 guidelines (cf. annex 5) Non inclusion
 criteria: patient dying during the anaphylactic shock

 Selection of controls: One control for each case will be included. Controls will be recruited
 solely at the Hospital BICHAT. Controls should correspond to the following:

 Inclusion criteria: Any patient of age 18 and over Hospitalized for a surgical intervention
 necessitating a neuromuscular blocking drug injection, without developing an anaphylactic
 reaction That had been informed of the particulars of the study and that had consented to
 participate in this study

 Non inclusion criteria: pregnant women NB: If a patient recruited as a control suffers from
 an anaphylactic reaction following neuromuscular blocking drug-injection, this patient will
 be considered a case, and other controls paired, one to this novel case and one to the
 original case patient.

 Pairing : Controls will be paired to cases based on the following criteria :

 - age :+/- 5 years

 -  sexe

 -  infectious status : infected/ non infected

 -  type of surgery: the different sub-classes are classified as follows: orthopedic,
 neurosurgery/visceral, urologic, gynecologic/vascular, cardiac, thoraco/maxillo-facial,
 ophthalmology, ENT/Other.

 -  Pharmacological class of the neuromuscular blocking drug used for surgery

 Duration of the study:Total duration: 26 months Inclusion period: 24 months

 Length of participation for a patient:

 Cases: 6 to 10 weeks Controls: the day of the surgery

 Sample collection Cases: at the time of the shock (blood and plasma sample, and, when
 necessary for the patient, bronchial aspiration liquid) and during the Allergology Anesthesia
 consult 6 to 10 weeks post anaphylactic reaction Controls: blood and plasma sample following
 the injection of neuromuscular blocking drug injection.

 All blood sampling (and eventually aspiration of bronchial fluids) required for this study
 are performed during the normal clinical management of case and of control patients, without
 any additional or non-conventional procedure of intervention, diagnosis or patient monitoring
 (non-interventional study). Supernumerary blood tubes are collected in addition to those
 collected during the normal clinical practice (10 ml on dry tube for serum/plasma and 10 ml
 on EDTA tube) at the same time (case and controls) and the bronchial aspiration fluid is kept
 for analysis instead of being discarded.

 An anaphylactic shock to neuromuscular blocking drug during anesthesia arises in minutes
 following injection/perfusion. Samples from case patients will therefore be collected in the
 30 to 60 minutes following injection/perfusion of the neuromuscular blocking drug, as it is
 already currently performed during surgery, and when the patient's condition has been
 stabilized. The investigators expect that surgical incisions will not be performed in most,
 if not all, case patients as the anaphylactic reactions occur before incisions are possible,
 i.e. just after injection/perfusion of the neuromuscular blocking drug. Samples from control
 patients will therefore be collected shortly after exposure to neuromuscular blocking drug
 and before surgical incisions are performed, to avoid the perturbations induced by this
 surgical act, especially regarding neutrophil activation

 Blood volume collected specifically for this study:

 -  case patient: 10 ml after the anaphylactic reaction, and during the
 Allergology-Anesthesia consult 6 to 10 weeks after the shock le choc.

 -  Control patients: 20 ml following neuromuscular blocking drug injection Samples
 collected in Lithium heparinate for the cell-based study will be sent the day of the
 anaphylactic reaction and the day of the Allergology-Anesthesia consult by an authorized
 delivery service to the Unity Allergologic molecular et Cellularise at Institute
 Pasteur.

 Samples collected on dry tubes (serum sample) will be housed in the sero-tec of Hospital
 BICHAT, and series of aliquots sent to Institute Pasteur upon request. Identical aliquots
 will be used to dose anti quaternary ammonium specific IgG, and specific IgE as currently
 performed at the Unity d'Immunologic Autoimmunity et Hypersensibility at Hospital BICHAT.

 When performed, bronchial aspiration fluids will be kept in part for the study of NETs in the
 Unity d'Immunologic Autoimmunity et Hypersensibility at Hospital BICHAT, and in part for
 analysis of cellular content and PAF levels at the Institute Pasteur, and accordingly
 delivered the same day in the respective laboratories.

 Cutaneous prick tests will be performed during the Allergology-Anesthesia consult 6 to 10
 weeks post-anaphylactic reaction.

 Following each inclusion, each hospital will send, as it is current medical practice,
 information on the patient: age, sex, type of surgery that was planned, nature of anesthetics
 used, history of atopic events including asthma, allergy to food or drugs, comorbidity
 factors. Control patients will be included at Hospital BICHAT only.

 Main judgment criteria:

 1. Percentage of circulating activated neutrophils in the group of patients immediately
 after a neuromuscular blocking drug-induced shock (case) compared to that of the group
 of patients exposed to neuromuscular blocking drug during anesthesia without developing
 a shock (control). This measure will be based on the intensity of expression of the
 activation marker CD62L (L-selectin) by blood neutrophils using flow cytometry. Our
 preliminary data indicate that the Mean Fluorescence Intensity (MFI) of CD62L is >450
 when considering " non-activated " neutrophils, and CD62L(MFI)<300 when considering "
 activated " neutrophils.

 2. Levels of PAF in the plasma of "cases" than in the plasma of "controls".

 Secondary judgment criteria:

 1. Levels of anti-quaternary ammonium specific IgG in the plasma of "cases" than in the
 plasma of "controls".

 2. Ex vivo activation capacity of blood neutrophils in the presence of neuromuscular
 blocking drug-IgG immune complexes

 3. Presence of Neutrophil Extracellular Traps in the bronchial aspiration fluid of "cases"

 Description of the patient population: A complete description of the entire population
 studied and of the groups will be performed. Variables will be described according to
 their distribution as appropriate (mean and standard deviation for variables with a
 normal distribution; median and interquartile range for variables with abnormal
 distributions; frequency and percentage for category criteria).

 Analysis - The distribution of variables representing the percentage of activated
 neutrophils between cases and controls, as well as each secondary judgment criteria will
 be compared using a conditional logical regression, adjusting on the matching criteria -
 To evaluate the correlation between percentage of activated neutrophils and the severity
 of the shock, or between the level of specific IgG and the severity of the shock, a
 linear tendency test in a general linear model will be performed.

 -  An analysis results obtained in sub-groups of patients defined based on the
 severity of the shock they suffered from, will also be performed

 -  Statistical tests will be bilateral and the risk of first degree will be fixed at
 5%.

 -  Description of the functional parameters of blood neutrophils at basal stage or
 following stimulation with neuromuscular blocking drug-IgG complexes (expression of
 FcRs and of activation markers, release of mediators, induction of NETs), and
 description of the "classical" immunological parameters of the anaphylactic shock
 to neuromuscular blocking drugs (prick test results, ex vivo activation potential
 of basophils).

 5 complementary studies will be performed on samples from patients included in the
 NASA study:

 -  IPAAQ (Identification and Pathologic effects of Anti-Quaternary ammonium
 antibodies), As it will require an additional 10ml sample of sera, a specific
 signed consent will be obtained from every patient included in the IPAAQ study.
 This serum sample will be taken during the allergology visit scheduled 6 to 10
 weeks post-anaphylactic shock.

 The aim of this study is to quantify, identify and purify the different IgG subclasses
 of anti-quaternary ammonium antibodies in the sera of patients that have undergone an
 anaphylactic shock during anaesthesia. The ability of immune complexes, composed of
 anti-quaternary ammonium antibodies and a neuromuscular blocking agent, to bind human
 IgG receptors and/or to activate human neutrophils and basophils in vitro will be
 evaluated. This analysis will enable determining if anti-quaternary ammonium
 IgG-neuromuscular blocking agent complexes may be pathogenic, and validating the
 anti-quaternary ammonium IgG diagnostic test, in addition to the anti-quaternary
 ammonium IgE test performed during normal clinical practice.

 -  NASAmAbs: Different populations of memory B lymphocytes (particularly IgG or IgE +)
 directed against a quaternary ammonium will be isolated from PBMCs of two "cases"
 who have agreed to participate in the study NASAmAbs, by flow cytometry using a
 Quaternary Ammonium (QA) coupled to a fluorescent protein (eg KLH). Genes encoding
 the variable domains of the heavy and light chains immunoglobulins (IgH and IgL)
 expressed by each cell B will first be amplified by RT-PCR, then cloned into
 vectors encoding the constant domains of immunoglobulins. These vectors will be
 transfected into cell lines and resulting recombinant monoclonal antibodies
 (chimeric human-mouse) will be produced and characterized in terms of specific
 reactivity against QA neuromuscular blocking agents (for ELISA), affinity for the
 ligand (by method of magnetic resonance surface), and poly and self-reactivity (by
 ELISA and indirect immunofluorescence). The recombinant antibody will be evaluated
 for their ability to activate cells in vitro in the presence of antigen (QA or
 NMBA) and as to their ability to induce anaphylactic shock in vivo, in transgenic
 mouse models expressing human receptor for the antibody.

 The aim of this project is to generate human recombinant anti- quaternary ammonium
 antibodies to assess their pathological potential (anaphylactogenic).

 As part of the study NASAmAbs, 1 additional 250ml pocket of blood EDTA will be collected
 either during a consulting with the allergologist either during a visit for this
 purpose.

 - NASA LYMPHAQ: The presence of T cells specific for drug allergens is documented in
 allergy to penicillin, but their presence and characteristics in the immediate allergy
 to muscle relaxants has not been described. The purpose of our ancillary study is to
 highlight these T cell by specific activation tests, to characterize phenotypically,
 quantify, and compare their frequency to that of healthy donors.

 The aim of this ancillary study is to identify T cell specific populations for
 quaternary ammonium in patients sensitive to NMBA.

 The research will be performed on mononuclear cells already isolated during the
 post-shock visit as part of the NASA study.

 -  NASA Quin: In a recent study, the team of Dr. ROUZAIRE revealed a high prevalence
 of sensitization to neuromuscular blocking drug in 17 patients allergic to
 quinolones: 53% versus 3.4% in a control population. As with pholcodine, quinolones
 could thus be a way of sensitization of neuromuscular blocking agents.

 The aim of this ancillary project is to confirm on a larger cohort, the association of
 sensitization between these two drug classes, neuromuscular blocking agents and
 quinolones.

 As part of the study NASAQuin, no additional blood sample will be collected. The
 research will be performed on aliquots of serum and / or plasma conserved as part of the
 study NASA. An aliquot of 300 µl will be used for the assay.

 -  NASA-CAT: Anaphylaxis can cause alone or during the administration of adrenaline,
 heart disease. The amplitude, frequency and pathophysiology of myocardial
 involvements are unknown.

 The aim of the ancillary study "NASA-CAT" is to define, using established plasma
 myocardial biomarkers , the prevalence of myocardial injury during anaphylaxis related
 to anesthetic agents and the role of adrenaline in this injury. Adrenaline is a
 catecholamine which is recommended to administrate intravenously in severe anaphylaxis.
 Adrenaline allows to restore immediately blood pressure due to its vasoconstrictor
 properties. Deleterious effects of adrenaline on coronaries and myocardium have been
 described in acute heart failure. The existence of similar effects in anaphylaxis is not
 known.

 The aim of the study "NASA-CAT" is to assess myocardial involvement in anaphylaxis and
 determine the role of adrenaline in this injury.

 As part of the ancillary study "NASA-CAT", no additional blood sample will be collected.
 The dosing of myocardial biomarkers (troponin hypersensitive, natriuretic peptides,
 adrenomedullin, copeptin) will be performed on samples of 500μl from serum and / or
 plasma stored in as part of the NASA study.
Selection of cases :

 INCLUSION CRITERIA:

 -  Any patient of age 18 and over:

 -  Presenting with clinical signs compatible with a perioperative anaphylactic reaction
 to neuromuscular blocking drugs, whatever the grade of the anaphylactic reaction

 -  That was treated following the French Patient Management 2011 guidelines

 EXCLUSION CRITERIA:

 - pregnant women

 Selection of controls:

 INCLUSION CRITERIA :

 -  Any patient of age 18 and over

 -  Hospitalized for a surgical intervention necessitating a neuromuscular blocking drug
 injection, without developing an anaphylactic reaction

 -  That had been informed of the particulars of the study and that had consented to
 participate in this study

 EXCLUSION CRITERIA: none